129 related articles for article (PubMed ID: 15351171)
1. Lymph-node-negative oestrogen-receptor-positive breast cancer.
Pansegrau GK; Gelmon KA
Lancet; 2004 Sep 4-10; 364(9437):820-1. PubMed ID: 15351171
[No Abstract] [Full Text] [Related]
2. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
[TBL] [Abstract][Full Text] [Related]
3. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
4. Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group.
Lundin AC; Söderkvist P; Eriksson B; Bergman-Jungeström M; Wingren S
Cancer Res; 1999 May; 59(10):2332-4. PubMed ID: 10344739
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of tamoxifen resistance.
Ring A; Dowsett M
Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444
[TBL] [Abstract][Full Text] [Related]
6. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
7. Re: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Atkins CD
J Natl Cancer Inst; 1998 Mar; 90(6):468-9. PubMed ID: 9521174
[No Abstract] [Full Text] [Related]
8. [Modern approaches to estrogen-independent growth of breast tumor].
Krasil'nikov MA
Vopr Onkol; 2004; 50(4):399-405. PubMed ID: 15605761
[No Abstract] [Full Text] [Related]
9. Tamoxifen therapy--long-term results and complications.
Moore MP; Kinne DW
Adv Surg; 1996; 29():263-9. PubMed ID: 8720007
[No Abstract] [Full Text] [Related]
10. Tamoxifen in early breast cancer.
Bryce CJ
Lancet; 1998 Aug; 352(9125):403. PubMed ID: 9717952
[No Abstract] [Full Text] [Related]
11. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen in early breast cancer.
Arriagada R
Lancet; 1998 Aug; 352(9125):403-4. PubMed ID: 9717953
[No Abstract] [Full Text] [Related]
14. [New developments in hormonal therapy for breast cancer].
Tominaga T
Gan To Kagaku Ryoho; 1996 May; 23(6):678-83. PubMed ID: 8645017
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
[TBL] [Abstract][Full Text] [Related]
17. Adverse outcome and resistance to adjuvant antiestrogen therapy in node-positive postmenopausal breast cancer patients-The role of p53.
Rahko E; Blanco G; Bloigu R; Soini Y; Talvensaari-Mattila A; Jukkola A
Breast; 2006 Feb; 15(1):69-75. PubMed ID: 16005229
[TBL] [Abstract][Full Text] [Related]
18. [How to optimize the clinical therapeutic protocol for triple-positive breast cancer].
Wang N; Wang YJ
Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):241-3. PubMed ID: 20510070
[No Abstract] [Full Text] [Related]
19. Segmental mastectomy and tamoxifen alone provide adequate locoregional control of breast cancer in elderly women.
Yeh S; Tan LR; O'Connell TX
Am Surg; 1997 Oct; 63(10):854-7. PubMed ID: 9322656
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen in early breast cancer.
Benson JR
Lancet; 1998 Aug; 352(9125):404-5. PubMed ID: 9717955
[No Abstract] [Full Text] [Related]
[Next] [New Search]
